אודות פרק זה
Learn more about Alzheimer's disease drug development and clinical trial design for small molecule therapies using biomarkers in Alzheimer's research, and AI in drug development.
Solving neurodegeneration requires redefining how we view the timeline of disease. While billions have been spent on amyloid research, Sacha Schermerhorn suggests we may be focusing on the wrong markers at the wrong time.
In this episode, Brandon Li sits down with Sacha Schermerhorn, the Founder and CEO of Babylon Biosciences, to explore his unconventional approach to one of medicine’s hardest problems. Sacha shares how a personal family diagnosis fueled a decade of research and the eventual creation of a company designed to amortize risk through orthogonal shots on goal.
The conversation covers the "Burning House" analogy for pathology, the strategy behind recruiting legendary drug hunters like John Macor, and the development of a specialized AI model with OpenAI to forecast the success of clinical trials. They also examine why the highest leverage for AI lies in late-stage development and asset selection rather than early-stage screening.
What You’ll Learn:
- Why treating amyloid is 20 years too late
- The "Burning House" analogy for prioritizing treatment vectors
- How to recruit the "Avengers" of drug discovery out of retirement
- Using fine-tuned AI models to predict clinical trial primary endpoints
- Why AI creates more value in late-stage development than early screening
- The potential for 12-month biomarkers to enable prevention trials
- Managing the ethical implications of public clinical trial prediction markets
About the Guest:
Sacha Schermerhorn is the Founder and CEO of Babylon Biosciences, a small molecule therapeutics company focusing on Alzheimer’s disease. His commitment to the field began at age 15 and intensified following his grandmother’s diagnosis. Sacha has successfully assembled a team of world-class drug hunters to apply innovative computational tools and deep scientific expertise toward solving neurodegeneration.
Episode Resources:
אנגלית
ארצות הברית
תעתיק 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
פרקים אחרים בפודקאסט הזה
In this episode of Power to the Patients, host Brandon Li speaks with Sonia Prashar, Founder and CEO of AIM Trials, about the future of psychiatry research and why patient-centric innovation is no longer optional. Drawing on more than 18 years of clinical research experience across multiple therap…
Psychiatric drug development may be overcomplicating progress while overlooking effective treatments. Brandon Li speaks with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, about why clinical outcomes should matter more than novel mechanisms.
Jacobsen argues that the field’s fi…
What if the most effective way to treat some of the most devastating brain disorders isn’t by targeting symptoms in isolation, but by repairing the brain’s most fundamental unit of communication itself?
In this episode of Power to the Patients, host Brandon Li sits down with Dr. Craig Erickson, Re…
In this episode of Power to the Patients, Brandon Li speaks with Dr. Lara Shirikjian, board-certified psychiatrist and Medical Director at CenExel, about what it truly takes to build effective, ethical, and scalable psychiatric research programs.
Drawing on over 20 years of clinical and research e…
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a system…
הצהרה: הפודקאסט והגרפיקה המוטבעים בדף זה הם מ-Brandon Li, שהוא רכושו של בעליו ואינו קשור או מאושר על ידי Listen Notes, Inc.
